title: Response to McKinnell et al's original article "cost-benefit analysis from the hospital perspective of universal active screening followed by contact precautions for methicillin-resistant Staphylococcus aureus carriers".
authors.affiliation: 1Clinical Effectiveness Unit,Department of Health,Dublin,Ireland.
authors.forename: Mary Teresa
authors.initials: MT
authors.lastname: O'Riordan
authors.affiliation: 2Health Technology Assessment Directorate,Health Information and Quality Authority,Dublin,Ireland.
authors.forename: Patricia
authors.initials: P
authors.lastname: Harrington
authors.affiliation: 1Clinical Effectiveness Unit,Department of Health,Dublin,Ireland.
authors.forename: Kathleen
authors.initials: K
authors.lastname: Mac Lellen
authors.affiliation: 2Health Technology Assessment Directorate,Health Information and Quality Authority,Dublin,Ireland.
authors.forename: Máirín
authors.initials: M
authors.lastname: Ryan
authors.affiliation: 4Department of Clinical Microbiology,Royal College of Surgeons in Ireland,Dublin,Ireland.
authors.forename: Hilary
authors.initials: H
authors.lastname: Humphreys
mesh_terms: D002353:Carrier State / Q000175:diagnosis*; D017721:Hospital Costs; D006801:Humans; D017053:Infection Control / Q000191:economics*; D008403:Mass Screening / Q000191:economics*; D055624:Methicillin-Resistant Staphylococcus aureus; D013203:Staphylococcal Infections / Q000175:diagnosis*